Drug Trial Radar · NCT07593391
An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jun 8, 2026
Primary completion
Oct 29, 2028
Study completion Nov 12, 2028
Sponsor
- Lead sponsor
- Neuren Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phelan- McDermid Syndrome.
Conditions
- Phelan-McDermid Syndrome
Interventions
NNZ-2591Drug
The study drug will be administered twice daily orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety and tolerability of NNZ-2591 as assessed by the incidence of adverse events across participantsTime frame: Baseline through Safety Follow-Up (Month 12)
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of ECG parameters events across participants.Time frame: Baseline through Safety Follow-Up (Month 12)
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as assessed by changes from Baseline assessments of vital sign parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as incidence of abnormal, clinically significant clinical laboratory parameters events across participants.Time frame: Baseline through Month 12
- Long-term safety and tolerability of NNZ-2591 as incidence of abnormal, clinically significant physical examination findings across participants.Time frame: Baseline through Month 12
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Neuren PMS-302 Site #116
Birmingham, Alabama · Recruiting
Neuren PMS-302 Site#122
Glendale, California · Recruiting
Neuren PMS-302 Site#103
San Diego, California · Recruiting
Neuren PMS-302 Site#111
San Rafael, California · Recruiting
Neuren PMS-302 Site#102
Chicago, Illinois · Recruiting
Neuren PMS-302 Site#109
Chevy Chase, Maryland · Recruiting
Neuren PMS-302 Site#106
Brookline, Massachusetts · Recruiting
Neuren PMS-302 Site#104
Lexington, Massachusetts · Recruiting
Neuren PMS-302 Site#101
New York, New York · Recruiting
Neuren PMS-302 Site#108
Cincinnati, Ohio · Recruiting
Neuren PMS-302 Site#115
Houston, Texas · Recruiting
Neuren PMS-302 Site#113
Charlottesville, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.